VisCardia, Inc.

VisCardia, Inc. specializes in developing innovative cardiac therapies, particularly an implantable device aimed at improving outcomes for heart failure patients through diaphragmatic stimulation. Founded in 2015 and headquartered in Beaverton, US, VisCardia, Inc. is focused on treating patients with heart failure using its novel therapy.

Peter Bauer serves as the CEO. The company has successfully completed 3 deals, with the most recent being on January 28, 2019, when it raised USD 0. 40 mn in VENTURE DEBT financing, contributing to a total amount raised of USD 12. 50 mn.

VisCardia's primary product is the Synchronized Diaphragmatic Stimulation™ (SDS® therapy), designed for treating heart failure patients, specifically those with reduced ejection fraction. This minimally-invasive device aims to enhance cardiac function through diaphragmatic stimulation and targets elderly patients facing mobility and quality of life challenges. The product has been involved in initial clinical studies in Europe, with findings expected to be presented at significant cardiology gatherings such as ESC, HFSA, ACC, and AHA. The revenue model for VisCardia revolves around its SDS® therapy, which involves selling the implantable device directly to healthcare institutions and forming partnerships with medical professionals.

The sales strategy includes B2B transactions primarily targeting hospitals and specialized clinics, focusing on heart failure treatment. Revenue may come from one-time device sales along with fees for support services, although specific pricing details are not publicly available. VisCardia plans to utilize its recent funding from January 2019 to advance the development of its SDS® therapy and explore new market opportunities in both the United States and Europe. The company is focused on expanding its presence in these regions by enhancing its product offerings and launching additional innovative therapies aimed at heart failure patients.